Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre-T-DM1 era cohort study
{{output}}
Background: Adjuvant trastuzumab emtansine (T-DM1) is the standard treatment for HER2-positive early breast cancer (EBC) patients who do not achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). Given... ...
